CNTG - Centogene reaches a milestone in Parkinson's Disease study

Centogene N.V. (CNTG) announced today that the company has reached a significant milestone in its Rostock International Parkinson's Disease ("ROPAD") study with the recruitment and genetic testing of 10,000 participants.Involving over 120 study sites across the globe, the global observational study focusing on the role of genetics in Parkinson's Disease (“PD”), is the largest study of its kind, according to the company.Noting the achievement as a pivotal point in the study, Peter Bauer, the chief genomics officer at Centogene said: “we hope to use these deep insights into Parkinson's disease genetics to diagnose patients at the earliest point possible and contribute to targeted Parkinson’s treatments.”In 2018, Centogene partnered with Denali Therapeutics (DNLI) for the targeted global identification and recruitment of Parkinson’s disease patients with mutations in the LRRK2 gene.Centogene said that the patients enrolled in ROPAD with an LRRK2 mutation will be eligible to join future therapeutic studies conducted by companies such

For further details see:

Centogene reaches a milestone in Parkinson's Disease study